{"name":"Solasia Pharma K.K.","slug":"solasia-pharma-k-k","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Darvias","genericName":"DARINAPARSIN","slug":"darinaparsin","indication":"Refractory peripheral T-cell lymphoma","status":"discontinued"}]}],"pipeline":[{"name":"Darvias","genericName":"DARINAPARSIN","slug":"darinaparsin","phase":"discontinued","mechanism":"Darvias works by inhibiting the enzyme glutathione S-transferase pi (GSTP1), which is involved in the cell's detoxification process.","indications":["Refractory peripheral T-cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWDJsWUZPWkI4dlBzUGExYktCd3BDSmh0NHhRd21RdHlyZDVLWGc1bEhHOVpTY1lsckpmVkFBMzJNOTZ2by1HOU8xb0kxZ080clR4d2g1WDQ4MlIxSFJVUUg1TE1rZXp5VUdZamVWWnlUS0JyTVBkRFNoMk5XSUc3VEo0emF6Yk1qRG9N?oc=5","date":"2026-04-03","type":"pipeline","source":"MSN","summary":"CHUGAI PHARMACEUTICAL CO., LTD. (4519) - MSN","headline":"CHUGAI PHARMACEUTICAL CO., LTD. (4519)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wJBVV95cUxPREE0QldybTRQX21Wc21EQmxmR3B3T3dCdlo5SHdxWXE5MnlyX1oxTHhSVVpfMHpKd013YjJJWlhycERRUTh2R2s0ZTJ1RGc3a3lHbGx1ZjV6TWJWdTNxYUpKM3MwdmlBV0FGTkpqNkNLeHRmZDFnSGlQanZST3VsTWtkbXltWjBOeWFWZHZ5OGQwV2pWUnIxUDhiQWctYVFmVjRDS3o1T3dyREVBQzBVNDVYQXY1X2VxMUpJUjNRcXZqa2dNWlhKbHZlTlpHR0pkMzFFUXUxWjd0M05PZWpYdTBjQ3Y3UWhiVVpkRkJSejJuTFR2SDh0NVJYZlpza0pueldfRlZTX1FJeTZJUHNhSGRCWW1IQ3Fna2p4dFJGV2JHLTkxMTRtMGJ2d3UyUTlqb3VEejM0RDNQREtGSFU5dzhSenZLN09idklBa29LLWZyTklIOENQOWZYUkpWQkZlV2hz?oc=5","date":"2026-03-31","type":"pipeline","source":"TradingView","summary":"Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue - TradingView","headline":"Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for wa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOM1ZlemlpNGdzRU5tMjhmYnBJY09TVkl4VnVqNWxGZER1N2lIcmtVQTJCWkZjTmZTMFpvRUw5U2ViM3VhN3BkUmFTb0tpaHRLQjZuRTczQi04dy1nb2syTEhoRk4tcE5IWW14Qi1UWkhxd2N2YVZ0MVdCU0E0ZjBSNWxkQjJaNnljVDY1Zm9xMm5tV1paNDB0WEh6c2R1Y2M?oc=5","date":"2026-03-24","type":"pipeline","source":"Meyka","summary":"4597.T Solasia Pharma (JPX) JPY 29.00 pre-market 24 Mar 2026: heavy volume - Meyka","headline":"4597.T Solasia Pharma (JPX) JPY 29.00 pre-market 24 Mar 2026: heavy volume","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeW93ckpTRExEd2VrRjZNRlpDLXhlaGxoNGFNTHczWkFNUEs1djRvd2hSeTZ4RmhlQlRyWk5GOE95aDBMZ3FaZUFGLXpPeTdhelhEVTNTTGJVR05KMlh0MWI1dDJOc2tJQXpnaWkyMWdHTVRGUnc4aTItNnlZbndHZVhrMXNKOHltaVZPcmM3NDMwUE5OS2trdHozRGFLUFdXdEdOdGZ1SDU?oc=5","date":"2026-03-20","type":"pipeline","source":"Meyka","summary":"47.16M intraday, 4597.T Solasia Pharma (JPX) Mar 2026: most active, watch catalysts - Meyka","headline":"47.16M intraday, 4597.T Solasia Pharma (JPX) Mar 2026: most active, watch catalysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPamlwbDhNczFKejhkbGRIMGhMcEtPZjNrNFFrZ2xUMmVORVJaN0ZUWUFXWkVZd2FSTk03ZldvQldocE0zZktSbzRZNENUaFkzZHMwZUJHVFRlbERrRWt3Zmp0OWVyS2diZnkzTHlqcHk2RW9meGZqc3Jrdm1ad2NqZUpLcnUzckpTbElrTXZIYkQ4M1dmQmlDWDBFSmt4T0VWb1JvYTdIRjVNckVzakl4QmFzUm54TjA?oc=5","date":"2026-03-13","type":"pipeline","source":"Meyka","summary":"4597.T Solasia Pharma (JPX) pre-market: JPY 32.00 most-active on 13 Mar 2026, catalysts ahead - Meyka","headline":"4597.T Solasia Pharma (JPX) pre-market: JPY 32.00 most-active on 13 Mar 2026, catalysts ahead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQNjgzTEhGREhRMnZTeGh3ejl0N3BvaHkyT0p2NFA5eVNXQlhhemZ3WjNTYzdHakFwQVM2cnZpWkN0cHUwQklRUkQ1QW1Jb2E0cnlEQjcwaEdfaGFWMnQxX0JvcGhjM3pXQjNjU3JJdG8wYlBuR3ZNSXEyRkFDMEhSOUtVT2p3MnR3Q3NTTXRFbDh6SmkzenpyS29mcU1XcDlOR0lSTHhPV3dxQlhnczNOZEt0Z180YVY2REw3RmVBSjVZSUtCdUZRUmpnUC1LMXd1bDNUTVl3?oc=5","date":"2026-01-08","type":"pipeline","source":"Biostock","summary":"Back on track: 2025 was a year of clinical progress for Isofol, which restarted studies with arfolitixorin - Biostock","headline":"Back on track: 2025 was a year of clinical progress for Isofol, which restarted studies with arfolitixorin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQ2xnQ19oeUZCZmVCQVFZRHRZd3FabTQwcnR2VE5US1RWbkZ3QklCVzNEWkl5SDRHcGVoUlZaLWlmT3hOVHF5OFpqRmhYckhCLVNtWUw0djZEVlJxM2plM3NoQUU5MjBVYkRvbE92d2ZNWWF0YzhiSHYzOW9xU1h0UVVTWm94M2wzdnh5VXp2Skpvc1p1OU1ROU1PRW1pcjFwUUV0RjdybjlKYWJtWklnZ0c0UUdFMFlhVG1sNDRMWDJRdw?oc=5","date":"2025-11-13","type":"trial","source":"Biostock","summary":"Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia - Biostock","headline":"Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxORDVCSy1fZk1PdWFWNTNDam5DVWd6NFVDM2NmR2NweFBOY0NOMDhlbC1ZMWhjYjFEcFZZcWpNZ2ZhUGxQVWVuWWptLUVFN1Bydm10elpTUXk0Sjk2MEktN2thTHFsYWhXMXZDQV9fNlpIR2dPNENJZWhKa2tpS1VVQ3VpNDExcEIzOEV5bmdKQUhWSEhoaXN1dFJjQmJFeVl2ZmhwVThfMkNUdnVDcHFFMVJsZmxNczQ4VlFUejAyV1Jldw?oc=5","date":"2023-09-13","type":"pipeline","source":"The Worldfolio","summary":"Solasia: a journey of developing high-quality pharmaceuticals for cancer patients. - The Worldfolio","headline":"Solasia: a journey of developing high-quality pharmaceuticals for cancer patients.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPdzlUanU2OWtsVzJHa05lMzFfT2Vpc1FXblpybFR2YkZaQWZodGxkSGxzVmhuLUMtRW1xS1kzeUJ0M3I1dkZPMW5LMTZuOEx2OXBBdHZQcEVxaXJ3X2l1VERiNjJVQnh3WmFYV2hrR0tuSnZTbjlRVVQ4RnQxeno2RHROdnRRTDNsMVE0ZHpDQjBUM1F6RnJFc2x3dmdGVTJaRVlF?oc=5","date":"2022-08-22","type":"pipeline","source":"businesswire.com","summary":"Solasia Announces Launch of Darvias® in Japan - businesswire.com","headline":"Solasia Announces Launch of Darvias® in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPRENoNDZRNnQ5UExBa2ZwMEVUbG0yS3NXN0dMV09CNHR5RHgxSVhrUDhmUDVjZnJXTklNX3lLaUVaYXdKLXpoYlpuYTBWTVdxV2FvWWpVcjBCSG5nMnp0T3VkOFFQY2wwdTQ1OXpxVTZHbEY4SC04NXZaNS1WV2MyclNaSFV1dHhBdGl2SmhnLVN5QUozcjBnS04wVUZ2WVpQWWV3V05XSzJZS0stTFhyNU5VeEFFcU1LeWhwUVRwRE1oSDRQa1JiUmRHb0pDYzdiZVFXQzQzOXJYRXRHNlVvYnpzdUxPZFlZTEotU2V4MjhlQQ?oc=5","date":"2021-10-26","type":"deal","source":"businesswire.com","summary":"Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02) - businesswire.com","headline":"Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}